Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR Background: A global named patient use (NPU) program for afatinib in patients with advanced/metastatic NSCLC who had progressed during prior therapy was conducted between May 2010 and January 2016 (Cappuzzo et al (2018) . Here we describe outcomes for patients at Asian centers, including 840 patients treated at centers in Taiwan. Method: Eligible patients had progressed after clinical benefit on prior erlotinib/ gefitinib and/or had an activating EGFR/HER2 mutation, had exhausted all other treatments, and were ineligible for afatinib trials. Patients received afatinib (starting dose: 30e50 mg/day). Dose modifications were guided by tolerability in individual patients. Time to treatment failure (TTF) was calculated from treatment initiation to discontinuation. Adverse event (AE) reporting was mandatory. Results: Data were collected from 2242 NSCLC patients in 10 Asian countries. Patients were heavily pretreated: 62% had received 2 prior chemotherapy lines, and for most, afatinib was at least 4 th -line therapy; almost all had received erlotinib/gefitinib (Table  1) . Among patients with known tumor biomarker status, 97% were EGFR mutation-positive (m+) (Taiwan subgroup: 100%). Median TTF was 7.6 months; EGFR m+, 7.2 months (Taiwan: 11.7 and 14.2 months respectively; Table 1 ). Median TTF was >12 months in patients with EGFR exon20 insertions (n¼23) and in those with HER2 mutations (n¼12) (also for the Taiwan subgroup). ORR was 24.4% (Taiwan: 4.3%): the disease control rates (DCR) were 78% and 97%, respectively (Table 1) . The most frequently reported AEs were rash and diarrhea; no safety signals were identified. Conclusion: This analysis from Asian countries in the afatinib NPU program revealed clinically meaningful TTF/ORR/DCR in this heavily pre-treated, refractory advanced NSCLC patient population, including activity in common and uncommon EGFR mutations. In Asian patients, TTF was numerically longer in patients with uncommon and HER2 mutations than in those with common EGFR mutations. The safety profile of afatinib was consistent with non-Asian centers. Thirty consecutively presenting patients with lung cancer to be treated with radiation therapy with or without chemotherapy. Study design: Prospective study of predictors of radiation pneumonitis in patients of carcinoma lung treated with radiation therapy with or without concurrent chemotherapy Endpoints: Primary endpoint: -1. All recruited patients underwent CRP, PFTs and 6-MWT before the start of treatment and subsequently at 3 and 6 months after treatment or at any time upon the development of radiation pneumonitis. 2. Patients were assessed at scheduled 4 weeks, 3 months and 6 months post completion of radiation therapy for clinics-radiological features of radiation pneumonitis. 3. At 4 weeks, assessment of symptoms and detailed clinical examination was done, no radiological tests were performed unless clinically warranted. Secondary endpoint: -The Mean Lung Dose (MLD) and other DVH parameters, calculated and documented during radiation treatment plan evaluation were correlated with the development of radiation pneumonitis. Results: On univariate analysis of dosimetric parameters, for development of grade 2 RP, total lung -PTV V5, total lung -PTV MLD (mean lung dose) and Ipsilateral lung -PTV V5 dose, and Gross tumour volume (GTV) were significant with p value of 0.010, 0.007 and 0.024 respectively. On Multivariate analysis, Total lung dose MLD and FEV1 (% predicted) were significantly associated with the development of grade 2 RP with p value of 0.048 and 0.040 respectively. Conclusion: Radiation pneumonitis occurred within three months of completing radiation therapy. There is significant loss of pulmonary function in patients who developed radiation pneumonitis. Pre-treatment value of pulmonary function test are important for predicting Radiation pneumonitis. We concluded that FEV1 % predicted value of less than 63.5 % is significant. Mean lung dose of total lung -PTV is also significant in predicting Radiation pneumonitis. We concluded that patients receiving more than 17.35 Gy as mean lung dose are prone to develop radiation pneumonitis. Location of tumour in lower lobe Gross tumour volume had a significant association with development of radiation pneumonitis. Hunan Cancer Hospital, Changsha/CN Background: Mesenchymal-to-epithelia transition (MET) exon 14 skipping (METex14) has been recognized as a potential driver alteration in lung cancers, and represents an emerging molecular target for lung cancer treatment. However, most studies about patient characterization and clinical outcomes of METex14-positive lung cancer were conducted in Caucasians, relevant data in Chinese patients were lacking. Here, we retrospectively characterized the clinical and molecular features of patients harboring MET mutations causing exon 14 skipping in a large cohort of Chinese lung cancers, and interrogated relevant clinical parameters associated with clinical outcomes of crizotinib treatment. Method: Genomic profiling data obtained from either plasma or tissue of 7,507 lung cancer patients with various histological types were screened to identify patients harboring METex14. Results: A total of 68 patients (0.91%), different from the frequency of Western population (3%), were identified to carry DNA alterations predicted to cause METex14 with a median age of 67.5, which is statistically significantly older than the whole cohort (p<0.001, t-test). In addition, METex14 has a female predominance (p¼0.036, Fisher's exact test). Mutation rates vary in different histological sub-groups: 0.80% in adenocarcinoma, 1.31% in squamous cell carcinoma, and 10.0% in sarcomatoid carcinoma. Collectively, a total of 68 variants (39 unique variants) predicted to cause METex14 were identified, including 7 point mutations and 10 indels affecting splice donor sites, 1 point mutations and 19 indels affecting splice acceptor sites, one point mutation at Y1003, one in-frame deletion within exon 14. Clinical outcomes of 18 METex14-positive patients treated with crizotinib were investigated. The median PFS and median OS were 7.3 and 8.5 months. Overall response rate in this sub-cohort was 22.2% (4/18) and disease control rate was 38.9% (7/18). Among them, METex14-positive patients harboring concurrent TP53 mutations had significant shorter OS than patients with wild type TP53 mutations (p¼0.0068). In addition, patients diagnosed as squamous cell lung cancers displayed favorable PFS and OS than adenocarcinomas (PFS, p¼0.39; OS, p¼0.26) . Although statistical significance was not achieved due to limited patient number of squamous cell carcinomas, this result warranted further investigation into this observation. Conclusion: We comprehensively characterized METex14 in Chinese lung cancer patients with various histological types. Our data revealed that METex14 defined a unique clinical and molecular subset of lung cancers in Chinese patients. Our study also improved the knowledge of survival stratification in METex14-positive lung cancers and might be helpful for clinical therapeutic strategy design. Keywords: lung cancer, MET exon 14 skipping, Crizotinib However, their prognostic roles in early stage NSCLC were not well defined. In this study we sought to identify the pure prognostic role of TP53 mutation and TMN in patients with completely resected stage I NSCLC. Method: 244 patients of stage I (T1a-cN0) NSCLC who had been completely resected with TP53 Mutation status and TMB data were collected from TCGA Database. TMB data was analyzed in 119 patients. Disease free survival (DFS) and overall survival (OS) were compared between TP53 mutation and wild-type mutation, higher TMN (>223.5) and lower TMN (<223.5). DFS and OS were estimated using Kaplan Meier methods and Cox regression models. Results: 244 patients were included in this study with 122 (50%) TP53 mutations. Multivariate analysis identified TP53 mutation tumors were associated significantly shorter OS (HR 2.31, 95%-CI 1.34 to 3.87; p¼0.002) and DFS (HR 1.80, 95%-CI 1.12 to 2.71;p¼0.005) compared to wild-type tumors. The TMN between TP53 mutation and wild-type mutation was significant (mean 332.1 vs 164.1; p¼0.001), TMN>223.5was associated with worse OS (HR 2.72, 95% CI 1.25-5.93, p¼0.012) and DFS (HR 1.79, 95% CI 1.01-3.15, p¼0.045). TMN>223.5 were identified as independent prognostic markers. Conclusion: TP53 and TMN＞223.5 are two independent prognostic factors in resected stage I lung adenocarcinoma. TP53 mutation might increase TMN which impact on the prognosis. Keywords: TP53, nsclc, TMN
